After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential “breakthrough therapy” fo…

One of the main targets in the war on drugs could well become a drug to treat the scars of war. The U.S. Food and Drug Administration (FDA) has designated 3,4-methylenedioxymethamphetamine (MDMA), better known as the illegal drug ecstasy, a "breakth…

Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder. Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A. J Cent Nerv Syst Dis. 2017 Aug 23;9:1179573517728090. doi: 10.1177/1179573517…

Electronic dance music (EDM) parties have historically been high-risk scenes for use of a variety of psychoactive substances. Studies over the past couple of years have found nightclub and festival attendees report high rates of use. These parties a…

Breakthrough Therapy Designation ensures that FDA will work closely with MAPS to complete Phase 3 trials as efficiently as possible MAPS and FDA have also reached agreement on design, primary endpoint, and statistical approach for Phase 3 trials P…

Methamphetamin-bezogene Störungen Clinical practice guideline: Methamphetamine-related disorders Dtsch Arztebl Int 2017; 114(26): 455-61; DOI: 10.3238/arztebl.2017.0455 Gouzoulis-Mayfrank, Euphrosyne; Härtel-Petri, Roland; Hamdorf, Will…